NGL FINECHEM
Back to Balance Sheet
|
NGL FINECHEM Last 5 Year Total Non-Current Liabilities History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Total Non-Current Liabilities | ₹32 Cr | ₹6.32 Cr | ₹6.24 Cr | ₹8.06 Cr | ₹11 Cr |
What is the latest Total Non-Current Liabilities ratio of NGL FINECHEM ?
| Year | Total Non-Current Liabilities |
|---|---|
| Mar2025 | ₹32 Cr |
| Mar2024 | ₹6.32 Cr |
| Mar2023 | ₹6.24 Cr |
| Mar2022 | ₹8.06 Cr |
| Mar2021 | ₹11 Cr |
How is Total Non-Current Liabilities of NGL FINECHEM Trending?
| Years | Total Non-Current Liabilities | % Change | |
|---|---|---|---|
| Mar2025 | ₹32 Cr | 406.36 | |
| Mar2024 | ₹6.32 Cr | 1.27 | |
| Mar2023 | ₹6.24 Cr | -22.60 | |
| Mar2022 | ₹8.06 Cr | -27.82 | |
| Mar2021 | ₹11 Cr | - | |
Compare Total Non-Current Liabilities of peers of NGL FINECHEM
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| NGL FINECHEM | ₹1,941.5 Cr | -1% | 6.9% | 143.5% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹463,815.0 Cr | 0.5% | 6.2% | 17.3% | Stock Analytics | |
| DIVIS LABORATORIES | ₹192,678.0 Cr | 4.7% | 9% | 7% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹161,323.0 Cr | -3.7% | 7.2% | 49.8% | Stock Analytics | |
| CIPLA | ₹114,585.0 Cr | -0.6% | 5% | -3.2% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹101,067.0 Cr | -1.9% | -4.6% | -2.8% | Stock Analytics | |
NGL FINECHEM Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| NGL FINECHEM | -1% |
6.9% |
143.5% |
| SENSEX | 0.8% |
1.8% |
-6.5% |
You may also like the below Video Courses